Skip to content

Immediate effects of Electrostimulation on vessel enlargement by the reaction of the cells on their wall and on the cellular signals of healthy and people with heart disease

Acute effects of Electrical Stimulation on endothelium-dependent vasodilation and biochemical markers of healthy and cardiac

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-53x476
Enrollment
Unknown
Registered
2018-03-31
Start date
2016-02-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chagas' Cardiomyopathy

Interventions

Ganglionic or placebo electrical stimulation will be applied randomly and acutely for 30 minutes in the experimental and control groups. The experimental group will be composed of 10 male volunteers w
Device
E02.331.800

Sponsors

Faculdade de Ceilândia da Universidade de Brasília
Lead Sponsor
Faculdade de Ceilândia da Universidade de Brasília
Collaborator

Eligibility

Sex/Gender
Male
Age
45 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criterias for healthy subjects were aged > 45 years; absence of previous history of disease or surgical procedure and functional alterations during initial assessment or found in anaminesis that may interfere with the assessment of FMD. The criterias for chagasic subjects were aged > 45 years; consistent symptoms with chagasic heart failure III-IV classes of New York Heart Association (NYHA); stable heart failure drug therapy; left ventricular ejection fraction < 45%.

Exclusion criteria

Exclusion criteria: Exclusion criterias for healthy subjects were complications or cognitive/psychiatric disorders that hinder the realization of the protocol; electrical stimulation intolerance. The exclusion criterias for chagasic subjects were decompensated heart failure; uncontrolled diabetes; history of recent infection (last 03 months); corticosteroid use (last 03 months); valvular heart disease; unstable angina; acute myocardial infarction (last 03 months); obstructive hypertrophic cardiomyopathy; heart failure due to pericardial disease or corrected valvular disease; history of pulmonary / smoking disease (last 12 months); peripheral vascular disease; chronic use of oxygen therapy; previous implantation of a pacemaker or cardiac defibrillator; and systolic blood pressure at rest > 200 mmHg.

Design outcomes

Primary

MeasureTime frame
Increase of the brachial artery dilation by at least 3% as measured by the flow-mediated dilation (FMD) technique obtained by ultrasound imaging. The analysis of the FMD should have been carried out until 04/30/2018.

Secondary

MeasureTime frame
Secondary outcomes are not expected.

Countries

Brazil

Contacts

Public ContactGerson Cipriano Junior

Faculdade de Ceilândia da Universidade de Brasília

cipriano@unb.br+55-061-981907111

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 22, 2026